U.S. FDA grants Breakthrough Therapy Designation to Pradaxa < sup > ® < /sup > (dabigatran etexilate) specific investigational antidote

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa < sup > ® < /sup > (dabigatran etexilate) specific investigational antidote

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news